BMO Capital Starts Radient Pharmaceuticals (RPC) at Outperform
Tweet
Share
E-mailGet Alerts RPC Hot Sheet
Price: $8.67 -3.24%
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BMO Capital initiates coverage on Radient Pharmaceuticals (NYSE: RPC) with a Outperform rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Radient Pharmaceuticals click here. For more ratings news on Radient Pharmaceuticals click here.
Shares of Radient Pharmaceuticals closed at $0.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ridgepost Capital to Sponsor IPEM Global 2026
- Evercore ISI Starts Alvotech SA (ALVO) at Outperform
- BMO Capital Reiterates Outperform Rating on Netflix (NFLX), Advertising Seen As a Key Lever
Create E-mail Alert Related Categories
New CoverageRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
